Cargando…

Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy

The cGAS-STING signaling pathway has emerged as a promising target for immunotherapy development. Here, we introduce a light-sensitive optogenetic device for control of the cGAS/STING signaling to conditionally modulate innate immunity, called ‘light-inducible SMOC-like repeats’ (LiSmore). We demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Dou, Yaling, Chen, Rui, Liu, Siyao, Lee, Yi-Tsang, Jing, Ji, Liu, Xiaoxuan, Ke, Yuepeng, Wang, Rui, Zhou, Yubin, Huang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482946/
https://www.ncbi.nlm.nih.gov/pubmed/37673917
http://dx.doi.org/10.1038/s41467-023-41164-2
_version_ 1785102281189883904
author Dou, Yaling
Chen, Rui
Liu, Siyao
Lee, Yi-Tsang
Jing, Ji
Liu, Xiaoxuan
Ke, Yuepeng
Wang, Rui
Zhou, Yubin
Huang, Yun
author_facet Dou, Yaling
Chen, Rui
Liu, Siyao
Lee, Yi-Tsang
Jing, Ji
Liu, Xiaoxuan
Ke, Yuepeng
Wang, Rui
Zhou, Yubin
Huang, Yun
author_sort Dou, Yaling
collection PubMed
description The cGAS-STING signaling pathway has emerged as a promising target for immunotherapy development. Here, we introduce a light-sensitive optogenetic device for control of the cGAS/STING signaling to conditionally modulate innate immunity, called ‘light-inducible SMOC-like repeats’ (LiSmore). We demonstrate that photo-activated LiSmore boosts dendritic cell (DC) maturation and antigen presentation with high spatiotemporal precision. This non-invasive approach photo-sensitizes cytotoxic T lymphocytes to engage tumor antigens, leading to a sustained antitumor immune response. When combined with an immune checkpoint blocker (ICB), LiSmore improves antitumor efficacy in an immunosuppressive lung cancer model that is otherwise unresponsive to conventional ICB treatment. Additionally, LiSmore exhibits an abscopal effect by effectively suppressing tumor growth in a distal site in a bilateral mouse model of melanoma. Collectively, our findings establish the potential of targeted optogenetic activation of the STING signaling pathway for remote immunomodulation in mice.
format Online
Article
Text
id pubmed-10482946
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104829462023-09-08 Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy Dou, Yaling Chen, Rui Liu, Siyao Lee, Yi-Tsang Jing, Ji Liu, Xiaoxuan Ke, Yuepeng Wang, Rui Zhou, Yubin Huang, Yun Nat Commun Article The cGAS-STING signaling pathway has emerged as a promising target for immunotherapy development. Here, we introduce a light-sensitive optogenetic device for control of the cGAS/STING signaling to conditionally modulate innate immunity, called ‘light-inducible SMOC-like repeats’ (LiSmore). We demonstrate that photo-activated LiSmore boosts dendritic cell (DC) maturation and antigen presentation with high spatiotemporal precision. This non-invasive approach photo-sensitizes cytotoxic T lymphocytes to engage tumor antigens, leading to a sustained antitumor immune response. When combined with an immune checkpoint blocker (ICB), LiSmore improves antitumor efficacy in an immunosuppressive lung cancer model that is otherwise unresponsive to conventional ICB treatment. Additionally, LiSmore exhibits an abscopal effect by effectively suppressing tumor growth in a distal site in a bilateral mouse model of melanoma. Collectively, our findings establish the potential of targeted optogenetic activation of the STING signaling pathway for remote immunomodulation in mice. Nature Publishing Group UK 2023-09-06 /pmc/articles/PMC10482946/ /pubmed/37673917 http://dx.doi.org/10.1038/s41467-023-41164-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Dou, Yaling
Chen, Rui
Liu, Siyao
Lee, Yi-Tsang
Jing, Ji
Liu, Xiaoxuan
Ke, Yuepeng
Wang, Rui
Zhou, Yubin
Huang, Yun
Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
title Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
title_full Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
title_fullStr Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
title_full_unstemmed Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
title_short Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
title_sort optogenetic engineering of sting signaling allows remote immunomodulation to enhance cancer immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482946/
https://www.ncbi.nlm.nih.gov/pubmed/37673917
http://dx.doi.org/10.1038/s41467-023-41164-2
work_keys_str_mv AT douyaling optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT chenrui optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT liusiyao optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT leeyitsang optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT jingji optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT liuxiaoxuan optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT keyuepeng optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT wangrui optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT zhouyubin optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy
AT huangyun optogeneticengineeringofstingsignalingallowsremoteimmunomodulationtoenhancecancerimmunotherapy